Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Bullboard Posts
Comment by stockman75on Apr 22, 2020 8:35am
160 Views
Post# 30937881

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:THTX Big buy today

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:THTX Big buy todayI agree, qwerty. The new guy always can do everything better than the old and of course it sounds great now. It is much like early dating, everything right now is optimistic and rosy.The new guy has all the answers and is so wonderful. Hard for me to believe he will make that much difference. I sure hope so. Regardless I am much more optimistic about the NASH prospects/possibilities than the existing business. But if we can get the existing business turned up a notch or two then all the better since it has been so disappointing. 

I hope Palinc is right about our new CEO!



qwerty22 wrote:

"..I seem to be the only one on this Board that sees the new Ceo as someone who will execute at least twice as much as the former Ceo"

the turnaround in your outlook is clear to see  :)


I think it depends on whether there are inherent headwinds in the clinics that will just stop doctors from changing their position wrt Trogarzos role in the mdr market. The drug is efficacious, little doubt there. Some patients are being maintained in virological states that are less than gold-standard. But there are arguments for this situation to continue and it would seem to have worked its way, unofficially, into clinical practise. It seems to me they already identified the problems awhile back. Can this guy really execute in such a different way? Was Luc really that bad? I'm sceptical until I see some evidence.
 






Bullboard Posts